Celyad, a Belgian biotech developing gene therapies for cardiovascular diseases and cancer, filed on Monday with the SEC to raise up to $115 million in an initial public offering.
Celyad's stock is currently traded on the Euronext Brussels and Euronext Paris under the symbol CYAD. Its market cap is about €450 million and it gained 5% on Monday.
The Mont-Saint-Guibert, Belgium-based company, which was founded in 2007, plans to list on the NASDAQ under the symbol CYAD. Celyad initially filed confidentially on March 31, 2015. UBS Investment Bank and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
